In the ever-evolving biotech landscape, the translation of monoclonal antibodies (mAb) from preclinical to clinical settings has emerged as a sophisticated scientific endeavor, hinging on the intricacies of pharmacokinetic target-mediated drug disposition (PK-TMDD) models. This process requires a keen understanding of allometric scaling principles and their underlying assumptions regarding TMDD parameters. The translation of mAb […]